Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 978 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin, glucophage Clear all
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Metformin Prostate Cancer Adjuvant Trial

NCT02176161
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Recurrent
Interventions
Metformin Hydrochloride Extended Release 750mg
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Metformin on AD Biomarkers

NCT01965756
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 25, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

NCT00449605
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Glimepiride, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

NCT00694057
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HE3286, Placebo
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
22
States / cities
Anaheim, California • Beverly Hills, California • Buena Park, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Sep 25, 2026, 5:34 AM EDT
Recruiting Early Phase 1 Interventional

Metformin for Premature Infants With Bronchopulmonary Dysplasia

NCT07120971
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD)
Interventions
Metformin (open-label)
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
7 Days to 6 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 25, 2026, 5:34 AM EDT
Active, not recruiting Phase 1 Interventional

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

NCT03889795
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Advanced Solid Tumor
Interventions
Metformin, Simvastatin, Digoxin
Drug
Lead sponsor
Danae Hamouda, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCT00401973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorders
Interventions
olanzapine, amantadine, metformin, zonisamide, Wellness education
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2009 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

NCT00400231
View directory record Official record
Conditions
Metabolic Syndrome x
Interventions
Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 25, 2026, 5:34 AM EDT
Recruiting Phase 3 Interventional

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

NCT05132439
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Metformin ER, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 25, 2026, 5:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metformin Use and Vitamin B12 Deficiency

NCT01136512
View directory record Official record
Conditions
Vitamin B12 Deficiency, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

NCT00865839
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer

NCT01666730
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
metformin hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 25, 2026, 5:34 AM EDT
Completed No phase listed Observational

Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food

NCT00818077
View directory record Official record
Conditions
Type 2 Diabetes, Currently Taking Metformin
Interventions
Continuous Glucose Monitoring of Carbohydrate Intake
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02420262
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
50
States / cities
Tuscumbia, Alabama • Anaheim, California • Bermuda Dunes, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Early Phase 1 Interventional

Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer

NCT02153450
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
Interventions
metformin hydrochloride, stereotactic radiosurgery
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 25, 2026, 5:34 AM EDT
Completed No phase listed Observational

TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study

NCT01364350
View directory record Official record
Conditions
Diabetes Mellitus Type 2 in Obese
Interventions
standard of care in general clinical practice
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 24 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

NCT02551874
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Metformin, Placebo, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Concord, California • Encinitas, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 25, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

NCT02111096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2409021, Sitagliptin, Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
26
States / cities
Concord, California • Fresno, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 25, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

NCT04039503
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 25, 2026, 5:34 AM EDT